Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 3 September 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 September 2026
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 October 2026
Monofocal intraocular lenses for cataract surgeryStatus:In developmentProgramme:HealthTech guidanceExpected publication date: 10 March 2027
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ianalumab for treating active Sjogren's disease ID6634Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vamikibart for treating uveitic macular oedema ID6671Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Miniature lens system implantation for advanced age-related macular degenerationStatus:In developmentProgramme:HealthTech guidanceExpected publication date: TBC
Excimer laser trabeculotomy for open angle glaucomaStatus:In developmentProgramme:HealthTech guidanceExpected publication date: TBC